Ross Moat - 01 May 2025 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
05 May 2025, 16:54:51 UTC
Prior SEC filing
01 May 2025
Next SEC filing
05 Jun 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Filing notes and source

Key filing fact

Ross Moat filed Form 4 for Kiniksa Pharmaceuticals International, plc (KNSA) on 05 May 2025.

Key facts

  • This page summarizes Ross Moat's Form 4 filing for Kiniksa Pharmaceuticals International, plc (KNSA).
  • 10 reported transactions and 6 derivative rows are listed below.
  • Accepted by SEC: 05 May 2025, 16:54.

Change

  • Previous filing in this sequence was filed on 01 May 2025.
  • Current net transaction value: -$103,649.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001857177 Primary reporting owner

Moat Ross

Relationship
CHIEF COMMERCIAL OFFICER
Address
23 OLD BOND STREET, THIRD FLOOR, LONDON, UNITED KINGDOM
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Signature date
05 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KNSA transaction

Class A Ordinary Share

Options Exercise

Transaction value
$68,376
Shares
+3,850
Change %
+41%
Price
$17.76
Shares after
13,265
Date
02 May 2025
Ownership
Direct
Footnotes
F1
KNSA transaction

Class A Ordinary Share

Sale

Transaction value
-$107,800
Shares
-3,850
Change %
-29%
Price
$28.00
Shares after
9,415
Date
02 May 2025
Ownership
Direct
Footnotes
F1, F2
KNSA transaction

Class A Ordinary Share

Options Exercise

Transaction value
$111,391
Shares
+6,272
Change %
+67%
Price
$17.76
Shares after
15,687
Date
05 May 2025
Ownership
Direct
Footnotes
F1
KNSA transaction

Class A Ordinary Share

Sale

Transaction value
-$175,616
Shares
-6,272
Change %
-40%
Price
$28.00
Shares after
9,415
Date
05 May 2025
Ownership
Direct
Footnotes
F1, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KNSA transaction Derivative

Performance Share Unit

Award

Transaction value
$0
Shares
+4,976
Change %
Price
$0.000000
Shares after
4,976
Date
01 May 2025
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
4,976
Exercise price
Footnotes
F4, F5, F6
KNSA transaction Derivative

Performance Share Unit

Award

Transaction value
$0
Shares
+5,225
Change %
Price
$0.000000
Shares after
5,225
Date
01 May 2025
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
5,225
Exercise price
Footnotes
F4, F5, F7
KNSA transaction Derivative

Performance Share Option

Award

Transaction value
$0
Shares
+8,043
Change %
Price
$0.000000
Shares after
8,043
Date
01 May 2025
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
8,043
Exercise price
$27.74
Footnotes
F5, F8
KNSA transaction Derivative

Performance Share Option

Award

Transaction value
$0
Shares
+8,303
Change %
Price
$0.000000
Shares after
8,303
Date
01 May 2025
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
8,303
Exercise price
$27.74
Footnotes
F5, F9
KNSA transaction Derivative

Share Option

Options Exercise

Transaction value
$0
Shares
-3,850
Change %
-10%
Price
$0.000000
Shares after
33,661
Date
02 May 2025
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
3,850
Exercise price
$17.76
Footnotes
F1, F10
KNSA transaction Derivative

Share Option

Options Exercise

Transaction value
$0
Shares
-6,272
Change %
-19%
Price
$0.000000
Shares after
27,389
Date
05 May 2025
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
6,272
Exercise price
$17.76
Footnotes
F1, F10
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 10 footnotes

Footnote F1

This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 3, 2024.

Footnote F2

This transaction was executed in multiple trades through a broker-dealer at prices ranging between $28.00 and $28.03. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

Footnote F3

This transaction was executed in multiple trades through a broker-dealer at prices ranging between $28.00 and $28.04. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

Footnote F4

Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee.

Footnote F5

The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement.

Footnote F6

The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the "FDA") of a biologics license application for KPL-387 for the treatment of pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions.

Footnote F7

The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

Footnote F8

The Performance Share Options shall vest and become exercisable, if at all, upon the submission to the FDA of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions.

Footnote F9

The Performance Share Options shall vest and become exercisable, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions.

Footnote F10

The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .